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Research
During fetal life, alterations in normal
prostate gland development can produce per-
manent changes that persist throughout
adulthood and may increase the risk of dis-
ease in later life (Ho et al. 2006; Risbridger
et al. 2005). The prostate differentiates from
the cranial region of the urogenital sinus
(UGS) (Marker et al. 2003). In humans, the
ﬁrst epithelial buds are observed in the lateral
region of the UGS during the tenth week of
gestation in a pattern that shows a remark-
able similarity to that of bud development in
mice and rats during the early phase of gland
genesis (Timms et al. 1994). Prostate ductal
budding begins on gestation day (GD) 17 in
mice (2 days before birth) (Timms et al.
1994). Prostate development is dependent
on 5α-dihydrotestosterone (DHT) produc-
tion from testosterone within the UGS
mesenchyme (Marker et al. 2003). Androgen
receptor expression in prostatic mesenchyme
is required for directing growth and branch-
ing morphogenesis of epithelial buds, pre-
sumably by induction of paracrine factors
secreted by mesenchyme (Cunha and
Donjacour 1987; Kokontis and Liao 1999).
During development, prostatic epithelial
cells exhibit little androgen binding, and
androgen receptor protein expression in
epithelium is not required for differentiation
(Cunha and Donjacour 1987; Prins and
Birch 1995; Timms et al. 1999). Therefore,
fetal mouse UGS mesenchyme cells provide
an informative model of endocrine control of
prostate development.
There is now considerable evidence that
estrogens modulate the activity of androgens
in regulating prostate development. The UGS
mesenchyme in mice and rats responds to
estrogens via estrogen receptor 1 (α), whereas
in the human prostate estrogen receptor 2 (β)
may mediate most responses to estrogens dur-
ing development (Adams et al. 2002; Prins
et al. 1998). Prostatic growth and androgen
receptor ligand-binding activity are perma-
nently decreased in response to high, pharma-
cologic doses of both natural and xenobiotic
estrogens during development (Prins and
Birch 1995; Rajfer and Coffey 1978;
vom Saal et al. 1997). In contrast, increases in
prenatal estrogen levels within the physiologic
range (the normal range for endogenous
estradiol) stimulate prostate development,
leading to permanently increased prostate size
and androgen receptor ligand-binding activity
(Gupta 2000; Timms et al. 1999; vom Saal
et al. 1997). 
Estrogenic endocrine disruptors have the
potential to alter prostate development in a
manner similar to that of endogenous estra-
diol. In this study, we chose to examine
bisphenol A (BPA), the monomer used to
make polycarbonate plastic and as an addi-
tive in many other plastic products. BPA is
produced in excess of 6 billion pounds per
year, and the potential for human exposure is
great due to leaching from plastic and plastic-
lined metal food and beverage containers, as
well as from dental sealants (Takao et al.
2002; Welshons et al. 2006).
We have proposed that one mechanism
by which fetal estrogen exposure stimulates
prostate development is by increasing pros-
tatic androgen receptor gene [Ar; GenBank
accession no. X53779 (Benson et al. 2007)]
expression, thereby increasing the androgen
responsiveness of the developing prostate,
leading to enhanced gland genesis and growth
(Richter et al. 2005; vom Saal et al. 1997). In
the present study we sought to determine
whether the endogenous hormone 17β-estra-
diol (E2), within its physiologic range, and the
manmade estrogenic endocrine disruptor
BPA, within the range measured in human
serum (Schönfelder et al. 2002), directly inﬂu-
ence Ar and estrogen receptor 1 (α) (Esr1;
GenBank accession no. NM_007956.2) gene
expression at the transcriptional level in fetal
mouse UGS mesenchyme.
Materials and Methods
Animals, housing, mating, and organ collec-
tion. CD-1 mice were purchased from
Charles River Laboratories (Wilmington,
MA) and bred at the University of Missouri
in a facility accredited by the Association for
Assessment and Accreditation of Laboratory
Animal Care. Animals were housed on corn-
cob bedding in standard polypropylene cages.
They received water puriﬁed by ion exchange
and carbon filtration from glass bottles.
Pregnant and lactating females were fed
Purina 5008 chow (Purina Mills, St. Louis,
MO). After being weaned, animals were fed
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BACKGROUND: Hormonal alterations during development have lifelong effects on the prostate gland.
Endogenous estrogens, including 17β-estradiol (E2), and synthetic estrogenic endocrine disruptors,
such as bisphenol A (BPA), have similar effects on prostate development. Increasing exposure to
estrogens within the low-dose, physiologic range results in permanent increases in the size and
androgen responsiveness of the prostate, whereas exposure within the high-dose, pharmacologic
range has the opposite effects.
OBJECTIVES: We tested the hypothesis that the low-dose effects of estrogens on the developing
prostate are associated with increased expression of androgen receptor (Ar) and estrogen receptor 1 (α)
(Esr1) genes in mesenchyme cells.
METHODS: Ar and Esr1 mRNA levels were quantiﬁed in primary cultures of fetal mouse prostate
mesenchyme cells treated with E2 and BPA. 
DISCUSSION: Ar and Esr1 mRNA expression increased in response to E2, with thresholds of 0.001
and 0.037 nM, respectively; and in response to BPA, with a threshold of 1 nM for both mRNAs.
We did not observe the expected inhibition of Ar mRNA expression by pharmacologic levels of E2
relative to unexposed cells. 
CONCLUSIONS: The observed induction of gene expression occurred at concentrations within the
range of free E2 previously shown to permanently increase prostate size, thus supporting the
involvement of direct effects of estrogens on gene expression in prostate mesenchyme. The effects
of BPA occurred within the range of concentrations currently measured in human serum, demon-
strating the vulnerability of developing tissues to xenoestrogens.
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were maintained at 25 ± 2°C under a
12 hr:12 hr light:dark cycle. Animals were
treated humanely and with regard for allevia-
tion of suffering. Animal procedures were
approved by the University of Missouri
Animal Care and Use Committee and con-
formed to the NIH Guide for the Care and Use
of Laboratory Animals (Institute of Laboratory
Animal Resources 1996). 
Tissue collection, primary cell culture, and
dosing. Timed-pregnant females were killed on
GD17 (mating = GD0) by CO2 asphyxiation,
and fetuses were removed from the uterine
horns. The bladder and UGS were removed
from male fetuses as previously described
(Timms et al. 1999; vom Saal et al. 1997). The
prostatic region of the UGS was removed from
the bladder at the bladder neck, and mesenchy-
mal cells were isolated as described by Gupta
(1999). Brieﬂy, UGS tissue was disrupted by
digestion with 3 mg collagenase type I/mL
(Sigma Chemical Co., St. Louis, MO) for
30–50 min at 37°C in a shaking water bath
followed by manual pipetting. Clumps of
epithelium were allowed to settle out, and sus-
pended mesenchymal cells were collected and
cultured in complete medium [RPMI-1640
without phenol red (Gibco, Grand Island, NY)
supplemented with 2 mM L-glutamine, 100 U
penicillin G sodium/mL, 100 mg streptomycin
sulfate/mL, and 0.25 mg fungizone/mL] with
10% (vol/vol) fetal bovine serum (FBS; U.S.
Bio-Technologies, Parkerford, PA). Cells were
grown to 95% conﬂuence and then passaged
by digestion with 0.05% trypsin in 0.53 mM
EDTA (Gibco) for 5 min at room tempera-
ture. Cell viability was assayed with alamarBlue
(BioSource International, Camarillo, CA)
according to the manufacturer’s instructions.
We characterized the cell-type composi-
tion of the UGS cell primary cultures by
immunofluorescent staining of cytokeratins
with mouse anti-pan-cytokeratin clone
PCK-26 ﬂuorescein isothiocyanate conjugate
(Sigma), and co-staining of the mesenchymal
cell marker vimentin with goat anti-vimentin
(Sigma) and rabbit anti-goat Cy3 conjugate
(Sigma) (Prins et al. 1991).
During experimental treatments with E2,
BPA, tamoxifen, and raloxifene, FBS was
charcoal-stripped to remove all hormones,
and cells were maintained in a constant back-
ground of 690 pM DHT (200 pg/mL). Cells
were treated with DHT rather than testos-
terone to control for potential treatment
effects on the intracellular concentration of
this high-affinity ligand for the androgen
receptor, which is formed from testosterone
in UGS mesenchyme cells in vivo, and also to
avoid the intracellular metabolism of testos-
terone to E2 by aromatase; DHT is not a sub-
strate for aromatase (Kokontis and Liao
1999). First passage cells were seeded onto
24-well plates at 7 × 104 cells/well in estro-
gen-free complete medium with 5% (vol/vol)
charcoal-stripped FBS, 5% (vol/vol) charcoal-
stripped horse serum (Sigma), 690 pM DHT
(Steraloids, Wilton, NH), and ITS supple-
ment (insulin-transferrin-selenium; Cambrex,
Walkersville, MD) for ﬁnal concentrations of
10 µg insulin/mL, 10 µg transferrin/mL, and
10 ng selenium/mL. Cells were maintained in
this estrogen-free medium for 3 days, with
one medium change, before the start of treat-
ments. E2, BPA, and tamoxifen were obtained
from Sigma. Raloxifene (LY 156,758) was
obtained from Eli Lilly (Indianapolis, IN).
During treatments with E2 and BPA, cells
were grown for 4 days, and the medium was
changed every day, except where noted. The
concentration of E2 in culture medium dur-
ing treatments was measured by radio-
immunoassay as previously described by vom
Saal et al. (1990).
Real time RT-PCR measurement of gene
expression. Total RNA was isolated with the
RNAqueous kit (Ambion, Austin, TX) accord-
ing to the manufacturer’s instructions. Total
RNA was quantiﬁed by absorbance at 260 nm.
Expression of speciﬁc mRNAs were measured
by one-step real-time reverse transcription-
polymerase chain reaction (RT-PCR) as
described by Bustin (2000), with the TaqMan
EZ RT-PCR kit (PE Applied Biosystems,
Foster City, CA) on the ABI PRISM 7700
Sequence Detection System (PE Applied
Biosystems). The concentrations of Mn2+,
probe, and primers were optimized for each
primer/probe set. Primer/probe sets for Ar,
vimentin (Vim; GenBank accession no.
NM_011701.3), and acidic ribosomal phos-
phoprotein P0 (Arbp; GenBank accession no.
NM_007475.2) were designed using Primer
Express software (PE Applied Biosystems)
and are shown in Table 1. Primers were
designed to span exon boundaries in order to
prevent amplification of genomic DNA.
Primers were synthesized by Invitrogen
(Carlsbad, CA), and probes were synthesized
by PE Applied Biosystems. The primer/probe
set for Esr1 was TaqMan Gene Expression
Assay ID Mm00433149_m1 (PE Applied
Biosystems), which spans Esr1 exons 3–4. 
The relative concentrations of specific
mRNAs in each sample were normalized to
total RNA per well, as described by Bustin
(2000) and Latil et al. (2001). Normalization
to total RNA allowed for comparisons between
independent experiments. In parallel experi-
ments, total DNA per well was measured by
fluorescence of Hoechst 33258 (Sigma), as
described by Labarca and Paigen (1980). From
these data, the average RNA/DNA ratio was
calculated for each treatment; we used these
values to convert the mRNA/total RNA meas-
urements to mRNA/DNA to assess the effect
of E2 and BPA on gene expression per cell.
Statistical analyses. Treatments were repli-
cated in three wells per experiment and at least
two, and in most cases more (up to 10), repli-
cate experiments. Outliers were detected with
Grubbs’ test (Grubbs 1969) and removed.
Treatment effects were evaluated on untrans-
formed data for RNA, and on reciprocals for
DNA and gene expression, with the analysis of
variance (ANOVA) general linear model pro-
cedure using SAS software (SAS Institute Inc.,
Cary, NC). We made planned comparisons of
means for each treatment relative to controls
using the least-squares means test only if the
overall ANOVA showed signiﬁcant treatment
effects. To avoid inflation of error rates, we
did not use multiple comparisons among all
treatments. The criterion for statistical signiﬁ-
cance was p < 0.05.
Results
Characterization of UGS cells and nominal E2
concentration in primary culture. Consistent
with previous reports (Gupta 1999), immuno-
ﬂuorescent staining for the mesenchymal cell
marker vimentin revealed no epithelial cells
in first passage cells treated for 5 days with
0.1 nM E2 or with no E2 (data not shown).
The UGS primary cell cultures that we exam-
ined were thus homogenous populations of
mesenchyme cells that retained mesenchymal
differentiation markers throughout the incu-
bation period.
After the initial administration of E2 in
culture medium, the E2 concentration slowly
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Table 1. Sequences of primers and probes for real time RT-PCR assays.
Gene Sequence (5´→ 3´) 5´ position in CDS Exon boundary
Ar
Forward TGTCAAAAGTGAAATGGGACC 1494
Reverse TGGTACTGTCCAAACGCATGT 1567 1–2 at 1553
Probe TGGATGGAGAACTACTCCGGACCTTATGGG 1516
Arbp 
Forward GAGATTCGGGATATGCTGTTGG 289 2–3 at 302
Reverse GGCGATGGCACCAGCC 351
Probe CAATAAGGTGCCAGCTGCTGCTCG 312
Vim
Forward GCACCCTGCAGTCATTCAGA 602
Reverse CCACTTTCCGTTCAAGGTCAA 673 3–4 at 660
Probe AGGATGTTGACAATGCTTCTCTGGCACG 623
CDS, coding sequence. decreased, presumably by metabolism, seques-
tration in cells, and/or binding to the tissue
culture dish. In more detail, E2 was adminis-
tered at a concentration of 1 nM, in the mid-
dle of the dose range in our experiment. The
concentration of E2 in medium decreased by
2 hr to approximately 90% and by 18 hr to
approximately 60% of the administered dose,
and then remained stable through the remain-
ing time period examined (up to 48 hr). 
In the experiments we conducted, test
chemicals were added to medium every 24 hr.
Thus, at the midpoint of the dose–response
curve tested, the actual E2 concentration in the
culture medium was approximately 60% of the
initial concentration at the time we collected
the cells for analysis of mRNA. Measurement
of DNA and RNA content and induction of
gene expression confirmed that bioactive
amounts of E2 were thus present at nominal
concentrations < 0.001 nM (Figures 1 and 2).
E2 induces growth of UGS mesenchyme
cells. E2 treatment induced a small increase in
cell growth and proliferation as indicated by
DNA and RNA content at doses of 0.01–
10,000 nM (Figure 1A, 1B). At 100,000 nM
E2, inhibition of cell growth and proliferation
was observed (Figure 1A, 1B). Cell viability
was not affected at any E2 dose tested (data not
shown). Subsequent experiments used a dose
range of 0.0001–10,000 nM in order to avoid
the cell growth–inhibiting effects of very high
doses of E2. Relative total RNA was induced to
a greater degree than DNA (Figure 1A, 1B).
The housekeeping genes Vim, a component of
the cytoskeleton in mesenchyme cells, and
Arbp, a component of the ribosome, were
examined to determine whether either could be
used as a reference gene. However, both of
these genes increased expression in response to
E2, consistent with a general induction of cell
growth (Figure 1C, 1D). Vimentin and acidic
ribosomal phosphoprotein P0 exhibited differ-
ently shaped dose–response curves, suggesting
differences in their mechanisms of transcrip-
tional regulation by E2. Because neither house-
keeping gene was an appropriate control gene,
expression of speciﬁc mRNAs was normalized
to DNA.
E2 induces the steroid receptor mRNAs Ar
and Esr1. Ar mRNA expression was induced
by E2 up to just over 2-fold above control lev-
els (Figure 2A). The observed threshold of
induction, 0.001 nM, is slightly higher than
the measured free serum E2 concentration of
0.00077 nM or 0.21 pg/mL in male mouse
fetuses on GD18 (vom Saal et al. 1997). The
increase in Ar mRNA with E2 dose was
monotonic up to 100 nM E2. At doses of
≥ 1,000 nM E2, Ar mRNA levels declined
relative to the maximum observed induction
at 100 nM E2. Inhibition of cell growth was
only evident at 100,000 nM E2. 
The induction of Ar mRNA by a physio-
logically relevant level of E2, 0.037 nM
(10 pg/mL), was significantly inhibited by
antiestrogen treatment (Figure 3A). The anti-
estrogen raloxifene (100 nM) had similar
effects to 100 nM tamoxifen (raloxifene data
not shown). The inhibition of the Ar response
to E2 by tamoxifen was overcome by addition
of a pharmacologic dose of 100 nM E2,
demonstrating that the inhibition by
tamoxifen observed at 0.037 nM E2 is not due
Richter et al.
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Figure 1. Indicators of cell growth increase with E2 dose. (A) DNA content slightly increased with E2 in a
dose-independent manner up to 10,000 nM and decreased significantly at 100,000 nM E2. (B) Total RNA
content increased with E2 in a dose-dependent manner up to 10,000 nM and decreased significantly at
100,000 nM E2. (C and D) Gene expression of the cytoskeleton protein vimentin (C) and the ribosomal com-
ponent acidic ribosomal phosphoprotein P0 (D) increased with E2 treatment. Units are fold induction rela-
tive to the control. Error bars represent 1 SE. The number of replicates measured for each treatment is
shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05).
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Figure 2. Biphasic Ar and Esr1 gene expression responses induced by E2. (A) Ar mRNA expression increases
with increasing dose of E2 up to a dose of 100 nM. A dose of 0.001 nM (0.27 pg/mL) is within the physiologic
range of free E2in mouse fetuses, and a signiﬁcant response to this dose is consistent with prior in vivo ﬁndings
(vom Saal et al. 1997). (B) Esr1 mRNA expression increases with increasing dose of E2 up to a dose of 100 nM.
Error bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05).
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(Figure 3A). 
Esr1 mRNA expression was induced by
E2 by approximately 3-fold over the control,
with a threshold at 0.037 nM (Figure 3B)
and a peak at 10–100 nM E2 (Figure 2B).
The induction of Esr1 mRNA by 0.037 nM
E2 was not significantly inhibited by anti-
estrogen treatment (Figure 3B).
BPA acts as an estrogen agonist in UGS
mesenchyme cells. The effects of BPA on cell
growth as indicated by DNA and RNA con-
tent (Figure 4) were much less pronounced
than the effects of E2 (Figure 1). The dose–
response curve for RNA was biphasic, with
significant reductions in RNA content, but
not DNA, at very low concentrations of BPA
(Figure 4). Ar and Esr1 mRNA expression
were induced by BPA treatment (Figure 5).
The dose–response curves for BPA were
shifted to the right by approximately
1,000-fold for Ar and approximately 30-fold
for Esr1, relative to E2 (based on the signiﬁ-
cant stimulation of Esr1 in response to
0.037 nM E2; Figure 3B). As indicated in
Figure 5A and 5B, a significant increase in
both Ar and Esr1 transcription occurred at
BPA concentrations within the range typically
reported in human blood and tissues, includ-
ing fetal blood (Schönfelder et al. 2002;
Welshons et al. 2006). The induction of both
Ar and Esr1 mRNAs by a physiologically rele-
vant low dose of BPA (10 nM) was inhibited
by a 100-nM dose of tamoxifen. For both
genes, the inhibition by tamoxifen was over-
come by a high dose of BPA (1,000 nM)
(Figure 6). 
Discussion
The aims of the present study were to investi-
gate whether there were direct effects on Ar
and Esr1 gene activity that could be related to
the previously observed stimulatory effect on
prostate development caused by prenatal
exposure to serum concentrations of bioactive
E2 in fetal mice and the concentration of
bioactive BPA currently measured in human
fetal serum. We found that both the natural
estrogen E2 and the synthetic estrogenic
endocrine disruptor BPA stimulated increases
in prostate Ar and Esr1 mRNAs. The stimu-
lation occurred at physiologically relevant
part-per-trillion doses of E2, and at parts-per-
billion doses of BPA, which are within the
range found in human fetal blood (reviewed
by Welshons et al. 2006).
Exposure of male mouse and rat fetuses to
slightly elevated estrogen levels results in per-
manent prostate enlargement and elevated
androgen receptor levels in adulthood
(Timms et al. 1999; vom Saal et al. 1997).
Some confusion concerning effects of estro-
gen on the prostate has been created by stud-
ies in which only very high, pharmacologic
(supraphysiologic) doses of estrogen were
tested. Effects of pharmacologic doses of
estrogenic chemicals on prostate development
are not predictive of effects at physiologic
doses. The dramatic effects of physiologic
doses of estrogens have been revealed in stud-
ies in which pregnant mice were administered
low doses of E2, the drugs diethylstilbestrol
(DES) and ethinylestradiol, BPA, or the
estrogenic insecticide methoxychlor, resulting
in a permanent increase in prostate size in
male offspring (Gupta 2000; Nagel et al.
1997; Thayer et al. 2001; vom Saal et al.
1997; Welshons et al. 1999). As the dose of
E2 or DES was increased into the pharmaco-
logic range, the stimulating effect observed at
low doses disappeared and inhibition of
prostate development occurred (Gupta 2000;
Timms et al. 2005; vom Saal et al. 1997).
Thus, the inhibitory effects of pharmacologic
doses of estrogens on the developing prostate
are opposite to effects of physiologic doses of
the same estrogenic chemicals. 
Available data on short-term effects of
developmental estrogen exposures are consis-
tent with the long-term effects observed in
adulthood. For example, a high, pharmaco-
logic dose of estradiol benzoate given to
neonatal rats induced down-regulation of
androgen receptor protein expression as early
as postnatal day (PND) 6 (Prins and Birch
1995). In contrast, low, physiologically rele-
vant doses of estrogenic chemicals (DES and
BPA) fed to pregnant mice induced up-regula-
tion of prostatic androgen receptor ligand
binding activity in male offspring as early as
PND3; this observation was replicated in
organ culture of fetal mouse prostate treated
with 0.1 pg/mL DES or 50 pg/mL BPA
(Gupta 2000). The increase in prostate size in
E2 and BPA induce Ar and Esr1 in fetal prostate
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Figure 3. Antiestrogen treatment inhibits E2-induced expression of Ar but does not signiﬁcantly inhibit E2-
induced expression of Esr1. (A) The antiestrogen tamoxifen (Tam) blocks induction of Ar mRNA by a
physiologic dose of E2, and the inhibition by Tam is overcome by a pharmacologic dose of E2. (B) Tam does
not signiﬁcantly inhibit induction of Esr1 mRNA by a physiologic dose of E2, or by a pharmacologic dose of
E2. Error bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05). **Signiﬁcant differences between the same E2 treatment with
and without Tam (p < 0.05).
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organ culture is below the threshold observed
for stimulation of either Ar or Esr1 gene
expression observed in the present study.
Our ﬁndings support the hypothesis that
prenatal exposure to elevated estrogen levels
permanently increases prostate size and
androgen responsiveness at least in part by
inducing Ar mRNA expression. Importantly,
the effects on Ar mRNA expression occurred
with a threshold at 0.001 nM E2 (0.28 pg/mL),
consistent with concentrations previously
shown to alter prostate development in vivo.
Speciﬁcally, the total serum E2 concentration
in male mouse fetuses on GD18 is approxi-
mately 0.35 nM (94 pg/mL), and the free
(unconjugated and unbound to plasma
proteins) serum concentration of E2 is
0.00077 nM (0.21 pg/mL), or 0.2% of total
serum E2 (vom Saal et al. 1997), similar to
findings in rats (Montano et al. 1995). An
increase in free serum E2 in male mouse
fetuses (due to maternal administration of
E2 via Silastic capsule) to 0.0012 nM
(0.31 pg/mL) signiﬁcantly increased prostate
size and the number of prostatic androgen
receptors in adulthood (vom Saal et al. 1997).
Our results show that at these same physio-
logic doses, E2 acts directly on fetal UGS
mesenchyme cells to increase Ar mRNA
expression. This response was inhibited by
the antiestrogens raloxifene (data not shown)
and tamoxifen (Figure 3), suggesting that
the induction of Ar mRNA by E2 is mediated
through the classical genomic estrogen
receptor pathway.
The differences in the shapes of the dose–
response curves for Ar and Esr1 suggest that
the receptors are regulated by distinct mecha-
nisms. Distinct dose–response relationships
were also noted for vimentin, acidic riboso-
mal protein P0, total RNA content, and
DNA content. These findings are consistent
with data from microarray studies demon-
strating considerable diversity in dose–
response relationships of different estrogen-
responsive genes; in particular, as one moves
across the dose–response curve, entirely differ-
ent sets of genes are activated or inhibited
(Coser et al. 2003; Shioda et al. 2006).
Induction of Ar and Esr1 also displayed dif-
ferent responses to inhibition by anti-
estrogens, in that Esr1 induction was not
significantly inhibited by antiestrogen co-
treatment (Figure 3). The threshold for effects
on Esr1 expression was between 0.01 nM
(2.3 ng/mL) and 0.037 nM (8.4 ng/mL) E2
(Figures 2B and 3B). This is above the nor-
mal range of free E2 in serum in male mouse
fetuses. However, serum estradiol may under-
estimate estrogen levels in prostate tissue
because cells in the developing prostate
express aromatase, which metabolizes testos-
terone to E2 (Ellem and Risbridger 2006;
Risbridger et al. 2003), and because estrogen
receptor agonists, including xenoestrogens,
exhibit additive effects in combination
(Rajapakse et al. 2002). The induction of
Esr1 expression by E2 suggests that estrogen
exposure may create a positive feedback loop
in the UGS, such that exposure to estrogens
increases sensitivity to future or continuing
exposure. 
Although the observed effects of physio-
logic concentrations of E2 on Ar mRNA
expression are consistent with established in
vivo effects, our pharmacologic dose range
(e.g., 100 nM) in vitro observations are not
consistent with established in vivo effects
(Gupta 2000; Prins and Birch 1995; vom Saal
et al. 1997), which predicted a decline in Ar
mRNA expression relative to control levels at
this high dose of E2 (Figure 2A). The in vivo
regulation of androgen receptors by pharma-
cologic doses of estrogens may thus involve
systemic and posttranscriptional effects that
are not observable in terms of Ar mRNA levels
in isolated mesenchyme cells. The involve-
ment of posttranscriptional mechanisms is
supported by the observation that develop-
mental exposure to pharmacologic doses of
estrogens permanently up-regulates androgen
receptor degradation by the proteasome
(Woodham et al. 2003).
The behavior of BPA in this system is
consistent with the established activity of BPA
as an estrogen receptor agonist (reviewed by
vom Saal and Hughes 2005; vom Saal and
Welshons 2006; Welshons et al. 2006), which
was first reported in 1936 (Dodds and
Lawson). The weak effects of BPA on cell
growth, measured as DNA and RNA content,
Richter et al.
906 VOLUME 115 | NUMBER 6 | June 2007 • Environmental Health Perspectives
Figure 5. Gene expression of Ar and Esr1 are induced by the synthetic estrogen BPA. (A) Ar mRNA expres-
sion increases with increasing dose of BPA. (B) Biphasic Esr1 mRNA expression response increases with
increasing dose of BPA up to a dose of 10,000 nM (10 µM or 2.28 µg/mL). Shaded areas represent the typi-
cal range of concentrations of unconjugated BPA measured in human serum (Welshons et al. 2006). Error
bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar.
*Values signiﬁcantly different from the control (p < 0.05).
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Figure 6. Antiestrogen treatment inhibits BPA-induced expression of steroid receptors Ar and Esr1. (A) The
antiestrogen tamoxifen (Tam) blocks induction of Ar mRNA by a 10-fold lower dose of BPA, and the inhibi-
tion by tamoxifen is overcome by a 10-fold higher dose of BPA. (B) Tam inhibits induction of Esr1 mRNA by
a 10-fold lower dose of BPA, and the inhibition by Tam is overcome by a 10-fold higher dose of BPA. Error
bars represent 1 SE. The number of replicates measured for each treatment is shown in each bar. 
*Values signiﬁcantly different from the control (p < 0.05). **Signiﬁcant differences between the same BPA treatment with
and without Tam (p < 0.05).
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15 15 11 11 86 6 6 99 89are consistent with previous reports that the
relative potency of BPA is greater in stimulat-
ing estrogen receptor–dependent gene tran-
scription than in stimulating growth of
uterine tissue (Nagel et al. 2001). There are
several interesting differences between the
dose–response curves of Ar and Esr1 in
response to BPA compared with E2. Based on
the thresholds of induction of gene expres-
sion, BPA is approximately 1,000-fold less
potent than E2 for induction of Ar, but only
about 30-fold less potent than E2 for induc-
tion of Esr1 (based on a threshold of Esr1
induction of 0.037 nM E2; Figure 3B). In
addition, the shape of the dose–response
curve for Esr1 differs between E2 and BPA;
induction of Esr1 by BPA was inhibited by
tamoxifen, whereas induction of Esr1 by E2
was not signiﬁcantly inhibited by tamoxifen.
These differences between E2 and BPA,
which are seen in the Esr1 dose–response
curves but not the Ar dose–response curves,
underline the probability that distinct mecha-
nisms are at work in the induction of Ar and
Esr1 by estrogens. 
Of great importance, the doses of BPA
required for induction of both Ar and Esr1
are within the range of typical levels of BPA
measured in human serum, which range
from approximately 1 to 10 nM (Figure 5)
(Schönfelder et al. 2002; Welshons et al.
2006). Because our experiments measured the
response to BPA in the absence of other estro-
gens, they are likely to underestimate the
induction of Ar and Esr1 expression in
response to the additive mixture of endoge-
nous estrogens, BPA, and other xenoestrogens
to which humans are continuously exposed in
our modern world (Colborn et al. 1993). The
consequences of developmental induction of
Ar and Esr1 for the adult phenotype of the
prostate have not been directly examined, but
exposure during fetal life to very low doses of
BPA (2–50 µg/kg/day) permanently increases
prostate size in mice (Gupta 2000; Nagel et al.
1997). Neonatal exposure to a 10 µg/kg/day
dose of BPA results in precancerous lesions
(prostate interepithelial neoplasia) in adult
male rats, associated with epigenetic changes
(Ho et al. 2006). The report of Ho et al.
(2006) is consistent with the finding that
estrogenic chemicals stimulate an abnormal
rate of proliferation in basal epithelial cells in
the primary ducts of the mouse fetal prostate
(Timms et al. 2005). Basal cells are progenitor
cells proposed to be involved in prostate can-
cer (Kirschenbaum et al. 2006). We are cur-
rently examining whether the permanent
increase in prostate AR receptor protein in
mice exposed during fetal life to low doses of
estrogenic chemicals is caused by a permanent
increase in expression of the Ar gene, and
whether this is associated with a change in
DNA methylation at the Ar gene.
Conclusions
Ar mRNA in mesenchyme cells isolated from
fetal mouse prostate is up-regulated by E2
within its physiologic range, and by BPA
within the range detected in human fetal
serum. Induction of Ar mRNA by E2 or BPA
was inhibited by antiestrogen co-treatment.
Therefore, the low-dose effects of estrogens
on prostatic Ar regulation are estrogen recep-
tor–dependent, act at the transcriptional level,
are mediated through local effects on UGS
mesenchyme cells, and can be modeled in a
primary cell culture system. In contrast,
down-regulation of androgen receptor protein
in response to high doses of estrogens in vivo
likely includes systemic and post-transcrip-
tional mechanisms. Esr1 mRNA is also up-
regulated by E2 and BPA in a dose-dependent
manner, suggesting the possibility of positive
feedback in estrogen effects on the prostate.
The induction of Esr1 by E2 is not signifi-
cantly inhibited by antiestrogen treatment,
suggesting the involvement of non-estrogen
receptor–mediated mechanisms.
Taken together, these results are consis-
tent with the hypothesis that prenatal expo-
sure to elevated estrogen or xenoestrogen
levels within the physiologic range results in
an increase in androgen receptor and estrogen
receptor 1 (α) number in the developing
prostate mesenchyme, which increases andro-
gen and estrogen responsiveness and growth.
The estrogen receptor–dependent induction
of Ar by BPA conﬁrms that this mechanism is
not unique to E2 and underscores the vulner-
ability of the developing reproductive system
to the additive effects of exogenous estrogenic
endocrine disruptors. 
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